MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3′ untranslated region by Yoon, A-rum et al.
MicroRNA-296 is enriched in cancer cells and
downregulates p21
WAF1 mRNA expression via
interaction with its 30 untranslated region
A-rum Yoon
1,2, Ran Gao
1,3, Zeenia Kaul
1,4, Il-Kyu Choi
1,5, Jihoon Ryu
1,2, Jane R. Noble
4,
Yoshio Kato
1, Soichiro Saito
1, Takashi Hirano
1, Tetsuro Ishii
3, Roger R. Reddel
4,
Chae-Ok Yun
6,*, Sunil C. Kaul
1,7 and Renu Wadhwa
1,7,*
1National Institute of Advanced Industrial Science & Technology (AIST), Central 4, 1-1-1 Higashi, Tsukuba,
Ibaraki – 305 8562, Japan,
2Brain Korea 21 Project for Medical Science, Department of Biomedical Science,
Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
3Majors of Medical
Sciences, University of Tsukuba, Ibaraki – 305-8575, Japan and
4Children’s Medical Research Institute,
214 Hawkesbury Road, Westmead 2145, NSW and Sydney Medical School, University of Sydney 2006, NSW,
Australia,
5Graduate Program for Nanomedical Science, Yonsei University, Seoul, South Korea,
6Department of
Bioengineering, College of Engineering, Hanyang University, Seoul, South Korea,
7Department of Biochemistry
and Molecular Biology, Yonsei University College of Medicine, Seoul, South Korea
Received December 27, 2010; Revised April 30, 2011; Accepted May 27, 2011
ABSTRACT
MicroRNAs (miRNAs) are a class of noncoding small
RNAs that act as negative regulators of gene ex-
pression. To identify miRNAs that may regulate
human cell immortalization and carcinogenesis, we
performed comparative miRNA array profiling of
human normal and SV40-T antigen immortalized
cells. We found that miR-296 was upregulated in im-
mortalized cells that also had activation of telomer-
ase. By an independent experiment on genomic
analysis of cancer cells we found that chromosome
region (20q13.32), where miR-296 is located, was amp-
lified in 28/36 cell lines, and most of these showed
enriched miR-296 expression. Overexpression of
miR-296 in human cancer cells, with and without
telomerase activity, had no effect on their telomer-
ase function. Instead, it suppressed p53 function
that is frequently downregulated during human cell
immortalization and carcinogenesis. By monitoring
the activity of a luciferase reporter connected to p53
and p21
WAF1 (p21) untranslated regions (UTRs), we
demonstrate that miR-296 interacts with the p21-
30UTR, and the Hu binding site of p21-30UTR was
identified as a potential miR-296 target site. We
demonstrate for the first time that miR-296 is
frequently upregulated during immortalization of
human cells and contributes to carcinogenesis by
downregulation of p53-p21
WAF1 pathway.
INTRODUCTION
MicroRNAs (miRNAs) were ﬁrst identiﬁed as regulators
of development in Caenorhabditis elegans. They have sub-
sequently emerged as a highly conserved class of non-
coding RNAs that act as suppressors of messengers
(mRNAs) by causing either their cleavage or translational
inhibition. This recent appreciation of the regulatory role
of small RNAs in mammalian systems has resulted in
numerous studies to investigate their function in the nor-
mal biology of development and differentiation, and in
disease phenotypes including cancers (1–6). miRNAs,
18–22-nucleotide (nt) in length, are transcribed as parts
of longer molecules called pri-miRNAs that are processed
in the cell nucleus into hairpin-structured pre-RNAs of
70–100nt by the double-stranded RNA (dsRNA)-speciﬁc
ribonuclease Drosha. Pre-miRNAs are exported from the
nucleus to the cytoplasm by Exportin-5 where Dicer
(a RNase III enzyme) cleaves them into 19nt mature
miRNAs with 1–4-nt 30 overhangs at either end. One of
the two strands of the mature miRNAs associates with an
RNA-induced silencing complex (RISC) and become
active miRNAs that suppress transcription of target genes
*To whom correspondence should be addressed. Tel: +81 29 861 9464; Fax: +81 29 861 2900; Email: renu-wadhwa@aist.go.jp
Correspondence may also be addressed to Chae-Ok Yun. Tel: +82 2 2228 8040; Fax: +82 2 2227 7751; Email: chaeok@yuhs.ac
The authors wish it to be known that, in their opinion, the ﬁrst two authors should be regarded as joint First Authors.
8078–8091 Nucleic Acids Research, 2011, Vol. 39, No. 18 Published online 30 June 2011
doi:10.1093/nar/gkr492
 The Author(s) 2011. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
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It is a well accepted concept in carcinogenesis that
nonrandom chromosomal abnormalities and accumula-
tion of mutations in the open reading frames of oncogenes
and tumor suppressors lead to loss of control of cell pro-
liferation in cancer cells. Recent studies now suggest that
the function of key genes may be altered by abnormal
miRNA expression in oncogenesis, and it has been pro-
posed that miRNA expression patterns may be used as
diagnostic ﬁngerprints and that miRNAs may be used as
anticancer therapeutics (11–20). Indeed, many miRNA-
encoding genes have been located at fragile sites in the
genome, as well as in minimal regions of loss/gain
associated with cancers (21). For example, miR-15a and
miR-16-1 genes are located at chromosome 13q14, a
region frequently deleted in pituitary tumors (22).
miR-21 was found to be overexpressed in highly malig-
nant human brain tumors, and was assigned functions
including inhibition of apoptosis, increased angiogenesis
and regulation of phosphatase and tensin homolog [PTEN
(23–26)]. Inhibition of miR-21 in cultured hepatocellular
carcinoma cells caused an upregulation of PTEN that was
associated with decreased tumor cell proliferation, migra-
tion and invasion (26–28). In miRNA proﬁling studies,
lung cancers were seen to have aberrant expression of
about 45 miRNAs providing a speciﬁc miRNA signature
(29). The let-7 miRNA family that negatively regu-
lates oncogenic Ras is frequently downregulated, suggest-
ing that let-7 miRNA has a tumor suppressor function
(30–31). Renal cell carcinoma was associated with up-
regulation of a set of four miRNAs (miR-28, miR-185,
miR-27 and let-7f-2); bladder cancers showed upregula-
tion of 10 miRNAs (miR-223, miR-26b, miR-221, miR-
103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a
and miR-205) (32); colorectal cancers were found to have
deregulated expression of miR-21, miR-31, miR-143 and
miR-145 (28); and breast cancers were associated with
increased miR-15a, miR-16, miR-17-5p, miR-21,
miR-29b, miR-125b, miR-145, miR-155, miR-181b and
let-7f (33). Furthermore, miR-29s was shown to regulate
DNA methylation patterns. Enforced expression of
miR-29s in lung cancer cell lines restored normal
patterns of DNA methylation and induced re-expression
of methylation-silenced tumor suppressor genes, such as
FHIT and WWOX, and inhibited tumorigenicity in vitro
and in vivo (34,35). The miR-34 family of miRNAs is
downregulated in several types of cancers (36–38). These
were shown to be induced by DNA damage and oncogenic
stress in a p53-dependent manner, and to modulate p53-
mediated apoptosis, cell cycle arrest and senescence by
suppression of BCL2, MYCN, SIRT1 and E2F functions
(39–44). p53 was also shown to regulate miRNA expres-
sion and processing several of them by interacting with
Drosha (45–47), suggesting that there is a complex net-
work of interactions in the regulation of tumor suppres-
sors, their effectors and regulators.
In contrast to normal cells, cancer cells undergo con-
tinued proliferation and have mechanisms to maintain
their telomeres, a most consistent manifestation of tumori-
genesis in vitro and in vivo (48,49). The telomere mainten-
ance mechanisms that get activated when cells escape from
crisis and become immortalized include either the upre-
gulation of telomerase activity or recombination-
mediated alternative lengthening of telomeres (ALTs)
(50). So far, no miRNAs have been shown to be involved
in the events that allow cells to escape from crisis and
become immortalized. In the present study, we used normal
human ﬁbroblasts and their SV40 T antigen-immortalized
derivatives that showed telomerase-dependent (Tel) or -in-
dependent (ALT) maintenance of telomeres. miRNA
array comparisons of the normal and telomerase positive
cells showed upregulation of miR-296 in telomerase-
positive immortal cells. Interestingly, miR-296 is located
on chromosome 20q13.32 that was detected as a Gain-
of-Locus in 28/36 of the cancer cell lines analyzed by
Comparative Genomic Hybridization-Bacterial Artiﬁcial
Chromosome (CGH-BAC) array. Molecular analyses of
the effects of synthetic miR-296, its antagonist and an
miR-296 expression plasmid in normal and immortalized
cells (both Tel and ALT) led us to conclude that miR-296
had no direct impact on telomerase activity. Instead, it
caused downregulation of the p53-p21
WAF1 pathway (a
major tumor suppressor pathway that is inactivated in
the majority of cancers). We report that the Hu binding
site of p21-30UTR is a potential target of miR-296 and it
therefore may promote carcinogenesis by downregulation
of p21
WAF1, in addition to its recently reported effects on
angiogenesis (51).
MATERIALS AND METHODS
Cell lines and cell culture
All normal cell strains and cell lines were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM; Gibco
BRL, Grand Island, NY,USA) supplemented with 10%
fetal bovine serum (Gibco BRL), penicillin (100IU/ml)
and streptomycin (50mg/ml) in the presence of 5% CO2
at 37
oC. Osteosarcoma (U-2 OS) cells were purchased
from the American Type Culture Collection (ATCC,
Manassas, VA, USA). Breast carcinoma cells (MCF 7)
and normal human ﬁbroblasts (TIG-1 and MRC5) were
obtained from the Japanese Collection of Research
Bioresources (JCRB, Japan). JFCF6 cells are normal
jejunal ﬁbroblasts from an individual with cystic ﬁbrosis,
and JFCF6/T22.5M, JFCF6/T1.J/1-3C and JFCF6/T1.J/
6B are SV40-immortalized ﬁbroblast lines derived from
JFCF6 (A. Englezou, P. Bonneﬁn and R. Reddel, unpub-
lished data). The latter two cell lines are referred to here as
JFCF6-3C and JFCF6-6B.
Telomeric repeat ampliﬁcation protocol assay
Telomerase was immunoafﬁnity puriﬁed from JFCF6 and
JFCF6-6/T22.5M whole cell lysates (10
6 cells in a total
volume of 200ml) as described previously (52). This par-
tially puriﬁed telomerase solution (2ml) was used in a 50ml
polymerase chain reaction (PCR) reaction with 0.1mg tel-
omerase primer M2, and 0.05mg reverse primer ACX
(53,54). Telomerase extension of the primer was carried out
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omerase extension products using 95 C for 2min and 30
cycles of 95 C for 10s, 50 C for 25s and 72 C for 30s.
pCXbG or pCXbG-miR296 transfected cells (5   10
5)
were collected and assayed for telomerase activity by Telo
TTAGGG telomerase PCR enzyme-linked immunosorb-
ent assay (ELISA; Roche, Mannhein, Germany). Serial
dilutions of known concentrations of cell extract
preparedfromimmortalizedtelomerase-expressinghuman
kidney cell (HEK 293 cells) were used to establish a
standard curve. U-2 OS cells were used as negative
control.
miRNA array
Small RNAs <200nt, including precursor and mature
miRNAs, were extracted from JFCF6 p12 [PD11] and
JFCF6/T22.5M p16 [PD45] cells with the mirVana
miRNA isolation kit (Ambion, Austin, TX, USA) follow-
ing the manufacturer’s protocol. Puriﬁed RNA was then
labeled with Cy3 or Cy5 using the mirVana miRNA
labeling kit (Ambion). Brieﬂy, RNA was subjected to a
tailing reaction with amine-modiﬁed nucleotide triphos-
phates by poly(A) polymerase, followed by amide forma-
tion using Cy dye ester. Labeled RNA was hybridized with
oligonucleotides against a set of 229 human miRNAs
arrayed on slides (Hokkaido-System Science, Japan),
and detected by a scanner (Agilent Technologies, Santa
Clara, CA, USA).
BAC array and CGH analysis
CGH analysis was performed on 24 breast cancer, seven
gall bladder and four bile duct cell lines as described earlier
(55,56). For CGH analysis, genomic DNA samples
(500 ng) from the test (cancer cells) and the reference
(human genomic DNA, Promega, USA) were labeled with
cyanine5-dCTP and cyanine3-dCTP (Perkin Elmer;
Fremont, CA, USA), respectively, in a random priming
reaction using Bioprime DNA Labeling System
(Invitrogen, Carlsbd, CA, USA) and Array Kit
(Macrogen, Korea). Un-incorporated ﬂuorescent nucleo-
tides were removed by QIAquick PCR Puriﬁcation Kit
(Qiagen, Germany). Labeled test and reference DNAs
were mixed in a solution (containing Cot
 1 DNA, 100ml
and Yeast tRNA, 4ml) (Macrogen) and were hybridized to
the CGH array (4030 BAC clone DNAs in duplicate,
covering the entire human genome with 1-Mbp resolution)
provided by Macrogen (MAC Array
TM KARYO 4000).
The entire process from hybridization (37
oC for 48–72h)
to washings [(i) 50% formamide/2X saline citrate at 46
oC
for 15min; (ii) 0.1% sodium dodecyl sulfate (SDS)/2 
SSC at 46
oC for 30min; (iii) PN buffer (0.1 MNa2PO4
and 0.1% NP40, Nakari Tesque, Japan) at 37 C for
15min; and (iv) 2  SSC at 37
oC for 5min] was performed
in a Hybri-station (Genomic Solutions, Ann Arbor, MI,
USA). The array slides were scanned at 532 and 635nm
using GenePix4000A (Axon Instruments, Union, CA,
USA) and analyzed by Mac Viewer software (Macrogen)
as described earlier (55,56).
Cloning of miR-296, expression plasmid design and
transfections
pCXGb-miR-296, a primary miR-296 region, was amp-
liﬁed from human genomic DNA by PCR using the fol-
lowing primers: 50-aactcgaggaccacgtgagcccttgt-30 and 50-aa
gatatc cgggagactgtggcaga-30. The PCR product was
digested with SalI and EcoRV and introduced into
pCXGb plasmid (generated from pCX-EGFP (57)
between the XhoI and EcoRV sites (Figure 2A).
The fragment encoding green ﬂuorescent protein (GFP)
fused with the blasticidin-resistance gene was ampliﬁed
by PCR using the primers 50-aaagaattcgccaccatggtgagc
aaggg-30,5 0-aaaaacaattgatatcactagtctcgagcggccgcctaggagc
cctcccacacataa-30, and 50-gacaaaggcttggcctggccatcgattttgt
acagctcgtccatgc-30 with pEGFP-C3 and pTracer-EF/bsd
as the templates. The resultant product was digested with
EcoRI and MfeI and inserted into the EcoRI sites of
pCX-EGFP to generate pCXGb.
Transfections of pCXbG or pCXbG-miR296 plasmids
were performed using Fugene (Roche Applied Science,
Indianapolis, IN, USA). Typically, 3mg of plasmid DNA
was used per 6-cm dish of cells at 60–70% conﬂuence.
Transfected cells were detected by GFP ﬂuorescence and
the GFP-miR296 was ampliﬁed by PCR (denaturation:
95
oC for 3min followed by 35 cycles of denaturation:
95
oC for 30s, annealing: 60
oC for 30s and extension
72
oC for 1min), on the genomic DNA of the transfected
cells using GFP (sense 50-taccagacaaccattacctg-30) and
miR-296 (antisense 50-gactcagcagctgacatgac-30) primers.
Synthetic precursor miR-296 (PmiR-296) and its
antagonist (AmiR-296)
Synthetic precursor miR-296 (PmiR-296) was purchased
from Ambion. 25 nM of PmiR-296 was transfected into
each cell type using Lipofectamine 2000 (Invitrogen). For
the inhibition of miR-296, 25 nM miR-296 inhibitor oligo-
nucleotide (AmiR-296, Ambion) that targeted miRNA-
296 3p or control oligonucleotides were transfected.
After 48h, the cells were trypsinized, and harvested for
further analysis.
Western blotting
Cells were lyzed in Nonidet P-40 lysis buffer in the
presence of protease inhibitors. Protein concentration
was determined using the BCA Protein Assay (Bio-Rad,
Hercules, CA, USA). Each sample (20–50 mg) was
separated by SDS–polyacrylamide gel electrophoresis
(PAGE). The proteins were then electroblotted onto a
polyvinylidene ﬂuoride (PVDF) membrane. Membranes
were blocked in TBS-T containing 5% dry milk. After
blocking, membranes were incubated with anti-p53
(DO-1) (sc-126; Santa Cruz Biotech, Santa Cruz, CA,
USA), and anti-p21 (C-19) (sc-397; Santa Cruz Biotech).
Actin was used as an internal loading control (anti-actin
antibody, Chemicon International, CA, USA). After
probing with the ﬁrst antibody as indicated, the blots
were incubated with HRP (horse radish peroxidase)-
conjugated secondary antibody (sc-2004 or sc-2005;
Santa Cruz Biotech). Finally, the blots were developed
8080 Nucleic Acids Research, 2011,Vol.39, No. 18using enhanced chemiluminescence (ECL) (RPN2132; GE
Healthcare, Buckinghamshire, UK).
Immunostaining
Cells were ﬁxed with prechilled (at  20 C) methanol/
acetone (1:1) mixture for 10min, rinsed thrice with
phosphate-buffered saline (PBS), and blocked with 2%
bovine serum albumin (BSA) for 1h. Cells were incubated
with appropriate primary antibodies at 4 C overnight.
The anti-proliferating cell nuclear antigen (PCNA; 2568;
Cell Signaling Technology) and p21 (sc-397; Santa Cruz
Biotech) antibodies were recognized by Alexa Fluor
488 anti-mouse immunoglobulin G (IgG, Invitrogen)
ﬂuorophore-conjugated secondary antibodies. For
40,6-diamidino-2-phenylindole (DAPI) staining, ﬁxed
cells were incubated in 1:500 of a stock solution of
DAPI (5mg/ml) at room temperature in dark for 30min
and were then washed with PBS. Actin ﬁlaments were
labeled with Alexa Fluor-Phalloidin (Red). Finally, the
stained cells were examined with a conventional ﬂuores-
cence microscope or confocal scanning laser microscopy
(Leica TCS SP2 AOBS microscope), using a 40 
objective.
RNA isolation, reverse transcription-PCR and
Quantitative PCR
For reverse transcription (RT)–PCR, total RNA was iso-
lated from cells at 48h post transfections using the
RNeasy mini kit (M1705; Qiagen, Standford Valencia,
CA, USA). Equal amounts of RNA (1mg) were used in
the RT reaction using oligo (dT)18 as the primer to
generate the ﬁrst-strand complementary DNA (cDNA),
and M-MLV reverse transcriptase (A1250; Promega,
Madison, WI, USA) was used to generate cDNA. The
cDNA from each sample was then subjected to one
round of PCR ampliﬁcation consisting of an initial
melting step (94 C for 5min) followed by a number,
optimized for each amplicon, of repetitive cycles (28–35)
consisting of denaturation at 94 C for 30 s, annealing at
55 C for 1min, and extension at 72 C for 30s using pri-
mers speciﬁc to p53, p21, and GAPDH (internal control)
mRNA. The primers used for the p21 RT–PCR were
50-gacaccactggagggtgact-30 (sense) and 50-ggcgtttggagtggt
agaaa-30 (antisense), for p53 were 50-aaggaaatctcacccca
tcc-30 (sense) and 50-aaggctgcagtaagccaaga-30 (antisense)
and for GAPDH (internal control) were 50-ACCACAGT
CCATGCCATCAC-30 (sense) and 50-TCCACCACCCT
GTTGCTGTA-30 (antisense). To determine the
quantitative-real-time PCR for p21 mRNA expression,
total RNA was isolated from U-2 OS cells using TRIzol
reagent. cDNA was synthesized using 5mg of total RNA,
oligo dT (2.5 mM) and Superscript Reverse Transcriptase
II (200U) in 20ml using an RT kit (Invitrogen).
Quantitative (Q)-PCR was performed using SYBR
Green Master Mix (Applied Biosystems, Carlsbad, CA,
USA). The following Q-PCR oligonucleotide primers
sets were used: p21 sense (50-cccgtgagcgat ggaact-30), p21
antisense (50-cgctcccaggcgaagtc-30), GAPDH sense (50-cccc
ttcattgacctcaactac-30) glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) antisense (50-tctcgctcctggaaga
tgg-30).
Cell proliferation and viability assays
The effect of miR-296 on cell proliferation was determined
by direct cell counting and by measuring the conversion of
the tetrazolium salt MTT to formazan. Brieﬂy, cells were
treated with precursor miR-296 or anti miR296 (30 nM) in
DMEM with 10% fetal bovine serum (FBS). After 2 days
of incubation at 37
oC, 200ml of MTT (Sigma Chemical
Corp., St. Louis, MO, USA) in PBS (2mg/ml) was added
to each well. After 4h of incubation at 37 C, the super-
natant was discarded and the precipitate was dissolved
with 100ml of dimethylsulfoxide (DMSO). Plates were
then read on a microplate reader at 540nm. Number of
living cells was calculated from untreated cells cultured
and treated with MTT in the same condition as in the
experimental groups. Control and transfected cells were
also stained for cell proliferation marker PCNA as
described above.
Cloning of pGL4(EB)-p53-30 untranslated region and
pGL4(EB)-p21-30UTR
pGL4(EB)-p53-30 untranslated region (UTR); p53-30UTR
region was ampliﬁed by PCR using human genomic DNA
with primers: 50-aaaGAATTCtgacattctccacttcttgttccc-30
and 50-aaaAGATCTtggcagcaaagttttattgtaaaataagag-30.
The PCR product was digested with EcoRI and BglII
and introduced into pGL4(EB) plasmid between EcoRI
and BamHI sites. pGL4(EB)-p21-30UTR; p21-30UTR
region was ampliﬁed by PCR using human genomic
DNA with primers: 50-aaaCAATTGTAAtccgcccacaggaa
gcctgc-30 and 50-aaaGGATCCtaaagtcactaagaatcatttattga
gcacctg-30. The PCR product was digested with MfeI
and BamHI and introduced into pGL4(EB) plasmid
between the EcoRI and BamHI sites.
Cloning of pGL4(EB)-HU and pGL4(EB)-p21-30UTR
Nucleotide sequences in the p21 30UTR mRNA (Hu
binding site and two candidate CU rich regions (CU
rich-1 and -2) were cloned into a reporter plasmid (58).
The Hu binding site consisted of 28nt (50-AATTC TCTT
AATTATTATTTGTGTTTTAATTTA G-30 and 50-GAT
CC TAAATTAAAACACAAATAATAATTAAGA G-
30). CU rich region-1 consisted of the following 32nt (50-
AATTC CCTCATCCCGTGTTCTCCTTTTCCTCTCT
CCC G-30 and 50-GATCC GGGAGAGAGGAAAAGG
AGAACACGGGATGAGG G-30) and CU rich region-2
consisted of 32nt (50-AATTC CTTCCTCATCCACCCC
ATCCCTCCCCAGTT G-30 and 50-GATCC AACTGGG
GAGGGATGGGGTGGATGAGGAAG G-30).
Annealing of the single strands was performed by
heating at 95 C (10min) followed by slow cooling
at room temperature. The double-stranded oligo-
nucleotides were digested with EcoRI and BamHI,
and cloned into pGL4(EB), generating luciferase-
expressing vectors (pGL4(EB)-HU, pGL4(EB)-CU1 and
pGL4(EB)-CU2) in which the luciferase open reading
frame was followed by a 30UTR containing the binding
site of interest.
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U-2 OS or MCF 7 cells were cultured in 12-well plates and
transfected with the luciferase constructs described above
[pGL4, pGL4(EB)-p53-30UTR, pGL4(EB)-p21-30-UTR,
pGL4(EB)-HU, pGL4(EB)-CU1 or pGL4(EB)-CU2
together with synthetic miR-296 (PmiR-296) or its antag-
onist (AmiR-296) using Lipofectamine (Gibco BRL)].
Luciferase assays were performed as described previously
(59). Cells were transfected with 500 ng of various
luciferase vectors using Lipofectamine (Gibco BRL).
Luciferase activity was measured as described in the
manufacturer’s manual (Luciferase assay kit; Promega)
with a luminometer and normalized to concentration of
total protein. Protein content was measured with a BCA
protein assay kit (Pierce Biotechnology, Rockford, IL,
USA). Experiments were carried out in triplicate and
repeated at least three times.
RESULTS AND DISCUSSION
Upregulation of miR-296 during human cell
immortalization
Growth curves of the parental JFCF6 cells and the SV40 T
antigen transformed clone JFCF6/T22.5M are shown in
Figure 1A. Whereas the parental JFCF6 cells underwent
only 20 population doublings (PDs) before permanently
ceasing proliferation, the JFCF6/T22.5M cells could be
passaged for more than 100 PD, suggesting that they
have undergone immortalization. They also showed acti-
vation of telomerase as demonstrated in Figure 1B. We
performed miRNA array analysis of the parental JFCF6
cells at PD11 and telomerase-positive JFCF6/T22.5M de-
rivatives at PD45, shortly after immortalization. As shown
in Figure 1C, miRNA array analysis showed increased
miR-296 (6.5-fold) and miR-155 (5.8-fold) expression in
JFCF6/T22.5M cells. Two other miRNAs miR-143 and
miR-145 were decreased in the immortalized JFCF6/
T22.5M cells as compared to their parental counterpart
JFCF6. We ﬁrst examined the chromosomal localization
of the genes encoding these miRNAs and investigated if
any of these were located on chromosome regions
commonly ampliﬁed in cancer cells by performing
BAC-CGH array on 36 cancer cell lines (Figure 2). As
shown, we found that the chromosome locus of miR-296
(20q13.32) (Figure 2A) was ampliﬁed in 28/36 cell lines
(Figure 2B). By genomic PCR using miR-296 speciﬁc
primers, ampliﬁcation of miR-296 was conﬁrmed in the
cancer cell lines (Figure 2C). In some cancer cell lines,
although ampliﬁcation of the chromosome region
20q13.32 was not detected by BAC-CGH array, genomic
PCR revealed ampliﬁcation of miR-296 as compared to
the control (Figure 2B and C). We presumed that this was
due to the different resolution of BAC-CGH and PCR
techniques. In order to verify that the gene ampliﬁcation
detected by PCR was not an artifact, we performed
miR-296 PCR on the genomic DNA isolated from blood
samples of 24 healthy individuals. In contrast to the
cancer cell lines that showed ampliﬁcation of miR-296
(3.08- to 7.2-fold as compared to the control; most cell
lines showed 3-fold or higher ampliﬁcation), none of the
24 normal genomic DNA samples showed miR-296 amp-
liﬁcation (data not shown). Since miR-298 is found to be
clustered with miR-296, we examined its status as well. As
summarized in Table 1, miR-298 showed ampliﬁcation in
most of the cancer cell lines; but followed a different amp-
liﬁcation pattern to that of the miR-296 (ampliﬁcation
ranged between 1.09- and 5.67-fold with many cell lines
showing <3-fold increase) indicating that miR-296 and
miR-298 might not be co-regulated. The data revealed
that the copy number of miR-296 and miR-298 is
increased in cancer cells, suggesting their involvement in
carcinogenesis.
miR-296 suppresses the p53-p21
WAF1 pathway
To examine the effect of miR-296 in cultured cells, we
constructed a miR-296 overexpression vector. A 389-bp
human genomic DNA fragment (encoding miR-296 pre-
cursor) was ampliﬁed by PCR on normal human genomic
Figure 1. miR-296 is upregulated in the SV40-immortalized
telomerase-positive JFCF6 cells. (A) Growth curves of JFCF6 and its
SV40 T antigen-immortalized derivative cell line JFCF-6/T22.5 M. (B)
Telomerase activity in parental JFCF6 and its immortalized cell line
JFCF6T/22.5 M. (C) miRNA array comparisons of the parental JFCF6
and a telomerase-positive immortalized derivative cell line, JFCF6/
T22.5M, showing upregulation of miR-296 (6.5-fold) and miR-155
(5.8-fold), and downregulation of miR-145 (0.24-fold) and miR-143
(0.25-fold) in the latter.
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continuity with GFP in pCXbGs vector, as illustrated
in Figure 3A. We ﬁrst conﬁrmed the occurrence of GFP-
miR-296 in transfected cells by PCR using GFP (sense)
and miR-296 (antisense) primers. As shown in Figure 3B,
expected size (750bp) PCR product was detected in the
pCXbGs-miR-296 transfected cells only. Since miRNA
array revealed an upregulation of miR-296 in telomerase-
positive JFCF6-derived immortal cells (Figure 1C),
we next investigated the relationship of miR-296 with
the telomerase activity. We generated miR-296
overexpressing telomerase-positive (MCF 7 and
JFCF6-6B) and telomerase-negative (U-2 OS and
JFCF6-3C) cells. The transfected cells were selected in
blasticidin (10mg/ml)-supplemented medium and were
seen to have bright GFP ﬂuorescence (Figure 3C) with
transfection efﬁciency of more than 80% both in
telomerase-positive and -negative cells. Control and
miR-296 transfected cells were assayed for telomerase
activity by telomeric repeat ampliﬁcation protocol
(TRAP) assay. However, as shown in Figure 3D, there
was no apparent difference in the level of telomerase
activity in control and miR-296 transfected
telomerase-positive or ALT cells.
In human cells, immortalization and activation of tel-
omerase are frequently associated with inactivation of
tumor suppressor protein p53 function, raising the possi-
bility of a link between these two pathways. It has also
been shown that the overexpression of wild-type p53
downregulates the enzymatic activity of telomerase in
various cancer cell lines through transcriptional repression
of the gene encoding its catalytic subunit, human telomer-
ase reverse transcriptase (hTERT) (60). We, therefore,
investigated whether miR-296 had any impact on this
pathway. As shown in Figure 4A, we found that the
level of p53 protein decreased in cells overexpressing
Figure 2. miR-296 is ampliﬁed in cancer cell lines. (A) Gene locus for miR-296 on chromosome 20q13.32. (B) Summary of the comparative genomic
hybridization (CGH) analysis of 36 cancer cell lines showing ampliﬁcation (+) of 20q13.32. (C) Genomic PCR of miR-296 on normal and cancer cells
showing ampliﬁcation of miR-296 in cancer cells.
Nucleic Acids Research, 2011,Vol.39, No. 18 8083miR-296 and was independent of the telomerase activity
status. Interestingly, p21
WAF1, a major downstream ef-
fector of p53 was found to be strongly suppressed in the
telomerase-positive line compared to the telomerase-
negative (ALT) line derived from the same parental
cells. In order to further investigate the role of miR-296
in regulation of the p53-p21
WAF1 pathway and to exclude
the effect of SV40 large T antigen, we used normal human
ﬁbroblasts with an active p53-p21
WAF1 pathway. We
found that miR-296 overexpression caused strong sup-
pression of p21
WAF1 expression in both TIG-1 and
MRC5 cells (Figure 4B and C). We also examined the
expression of p53 by immunostaining at a single cell
level in control and miR-296 vector transfected U-2OS
and MCF7 cells (both have wild-type p53). Whereas
75–80% of control cells showed bright p53 nuclear
staining, only 3–5% of the miR-296 vector transfected
cells (GFP ﬂuorescence) showed such staining in both
U-2 OS and MCF7 cells (Figure 4D and data not
shown) demonstrating an inactivation of p53 by miR-296.
In order to conﬁrm the above ﬁndings, we next used a
synthetic precursor RNA for miR-296 (PmiR-296) and its
inhibitor/antagonist (AmiR-296) that target miR-296 3p.
At ﬁrst, the effect of synthetic precursor and inhibitor was
examined by RT–PCR on the transfected cells. As
expected, the introduction of PmiR-296 resulted in an
increase and of AmiR-296 in the decrease of miRNA-
296 (Figure 5A). Furthermore, PmiR-296 transfected
telomerase-positive (MCF 7 and JFCF6-6B) and normal
(MRC5) cells showed strong suppression of p21
WAF1
(Figure 5B). Co-transfection of PmiR-296 and its inhibitor
(AmiR-296) partially canceled the suppressive effect of
PmiR-296 on p21
WAF1. The level of p21
WAF1 in the
untreated ALT cells (U-2 OS and JFCF6-3C) was lower
than in the telomerase-positive cells, and remain un-
changed in response to PmiR-296 treatment. However,
the transfection of AmiR-296 caused an increase in both
p53 and p21
WAF1 levels. The data suggest that the
p53-p21
WAF1 pathway is regulated by miR-296. Of note,
the effect of PmiR-296 on p53 (Figure 5B) was weak as
compared to the miR-296 expressed from the vector
(Figure 4). Since the protein levels are affected by their
stability and interaction with other proteins (especially in
case of wild-type p53 that is rapidly degraded), we
Figure 3. Exogenous miR-296 expression did not affect the telomerase
activity. (A) Diagrammatic presentation of miR-296 expression vector,
pCXGb-miR-296. The plasmid contained CMV enhancer/chicken
b-actin promoter (CBA) driving the expression of the inserted
miR-296 in continuity with enhanced GFP (EGFP) protein.
Polyadenylation sequence p(A) was added to its 30-end. The vector
contained Simian Virus 40 (SV40) origin of replication (ori), blasticidin
resistance (bsdR)- and ampicillin resistance (Amp
R)- encoding se-
quences. (B) PCR amplication of GFP-miR-296 from control and
miR-296 expressing vector transfected cells. (C) Exogenous expression
of EGFP-miR-296 in human cancer cells with (MCF 7) and without
(U-2 OS) telomerase activity. (D) Telomerase activity in control (1) and
miR-296 transfected (2) cells showing no change in the telomerase
activity in either the telomerase-positive (MCF 7) or -negative (U-2
OS) cells.
Table 1. miR-296 and miR-298 ampliﬁcation in cancer cells
Cell line miR296 miR298
BT-474 3.10 ND
HCC2218 3.08 4.00
MDA-MB-231 3.18 1.09
SKBR3 6.74 3.92
MDA-MB-435S 6.36 2.29
AU565 4.62 1.45
MDA-MB-468 7.24 1.73
HCC1428 5.03 1.91
HCC1954 3.29 5.69
HS578T 3.20 4.27
HCC1008 3.78 3.18
UACC812 5.85 5.15
UACC893 5.36 1.18
HCC1937 3.76 4.36
MDA-MB-361 3.07 2.36
ZR-75-1 4.08 2.98
BT-483 3.91 4.00
T47D 2.40 5.09
MDA-MB-175-V11 2.31 4.75
MDA-MB-415 3.18 3.35
HCC1806 3.23 1.55
ZR-75-30 3.68 2.96
GAPDH was used as an internal control and the relative ampliﬁcation
(fold increase over the control, normal genomic DNA) in respective cell
lines is shown. ND, not determined.
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WAF1 transcripts by
RT–PCR. As shown in Figure 5C, PmiR-296 caused
decrease in p53 and p21
WAF1 transcripts, although to a
different extent in different cell lines. Furthermore, a
clear increase, both in p53 and p21
WAF1 transcription
with AmiR-296, and an antagonistic effect of PmiR-296
on AmiR-296 were detected (lanes 3 and 4, Figure 5C).
These data conﬁrmed that the miR-296 downregulates the
p53-p21
WAF1 pathway. We also examined the effect of
PmiR-296 and AmiR-296 on cell proliferation. Transient
Figure 4. Exogenous miR-296 expression inactivated the p53-21
WAF1 pathway. (A) Immortal JFCF6-derived cells (6B, telomerase-positive and 3C,
telomerase-negative) cells transfected with miR-296 showed decreased levels of p53. p21
WAF1 showed decrease in telomerase-positive (JFCF6-6B) cells
only. (B) Normal human ﬁbroblasts transfected with miR-296 expression vector showing GFP ﬂuorescence. (C) Normal human ﬁbroblasts trans-
fected with miR-296 showed a decrease in p21
WAF1 protein. (D) Single-cell immunostaining for p53 in control and pCXbG-miR-296 transfected U-2
OS cells. Cells showing GFP ﬂuorescence (GFP-miR-296) either lacked or showed faint nuclear staining for p53 (red).
Nucleic Acids Research, 2011,Vol.39, No. 18 8085transfection of the synthetic precursor of miR-296,
PmiR-296, caused a 10–20% increase in cell number
(observed at 48–60h after the transfection); AmiR-296
led to a decrease in proliferation that was partially
compensated by co-transfection of PmiR-296
(Figure 6A). Consistent with these data, (i) PmiR-296
resulted in an increase and AmiR-296 in decrease in via-
bility of both MCF7 and U-2 OS cells (Figure 6B);
(ii) PmiR-296 transfected OS cells showed increase in the
level of cell proliferation marker PCNA (Figure 6C);
and (iii) human normal cells (TIG-1) stably trans-
fected with miR-296 showed increased proliferation
(Figure 6D). Taken together, we report for the ﬁrst time,
that miR-296 downregulates the p53-p21
WAF1 path-
way and result in increased proliferation and viability of
cells.
p21
WAF-1 is a potential target for miR-296
In order to further investigate whether p53 and/or
p21
WAF1 are the targets of miRNA-296, we generated
luciferase reporter plasmids having either the p53 30UTR
or the p21
WAF1 30UTR at the 30 terminus of the luciferase
open reading frame, as shown in Figure 7A. Cells were
transfected with these reporters along with either the con-
trol vector or PmiR-296 expressing vector. We found
that miR-296 had a weak but signiﬁcant effect on the
luciferase-p53-30UTR. On the other hand, it caused
robust suppression of luciferase-p21
WAF1 30UTR expres-
sion (Figure 7B). These data suggested that miR-296
targets both p53 and p21
WAF1, the latter being a
stronger target. Of note, it did not have any typical seed
sequence for miR-296 in its 30UTR. Several recent studies
have reported that p21
WAF1 mRNA levels are regulated
not only at the transcriptional level, but also at the post-
transcriptional level. The stability of p21
WAF1 mRNA is
controlled by Hu proteins that speciﬁcally bind to an
AU-rich element in its 30-UTR (58,61,62). Therefore, we
subcloned the p21
WAF1-30UTR to the 30UTR of luciferase
as three fragments (HU region, CU rich region 1 and CU
region 2) (Figure 7C and D) and investigated the effect of
miR-296 on expression of these constructs. We found
that the transfection of miR-296 decreased the ex-
pression of the construct containing the HU region
Figure 5. miR-296 regulates p53-p21
WAF1 pathway. (A) RT–PCR ampliﬁcation of miR-296 from cells treated with either precursor PmiR-296 or
antagonist AmiR-296. (B) p53 and p21
WAF1 protein levels in cells transfected with synthetic precursor miR-296 (PmiR-296) and antagonist
(AmiR-296) of miR-296. PmiR-296 transfected cells showed decreased levels of p53 and p21
WAF1 proteins. The decrease was more pronounced
in telomerase-positive (MCF 7 and JFCF6-6B) than in the telomerase-negative (U-2 OS and JFCF6-3C) cells. PmiR-296 transfected normal human
ﬁbroblasts showed a sharp decrease in p21
WAF1. Cells transfected with miR-296 antagonist (AmiR-296, Lane 3) showed an increase in p21
WAF1 and
co-transfections of AmiR-296 with PmiR-296 (lane 4) partly antagonized the effect of PmiR-296 (lane 2). (C) RT–PCR analysis for miR-296
transcript in cells transfected with synthetic precursor miR-296 (PmiR-296) and antagonist (AmiR-296) of miR-296. PmiR-296 caused reduction
in p53 and p21
WAF1 transcripts (lane 2). AmiR-296 caused increase in miR-296 transcript (lane 3) and decrease in p53 and p21
WAF1 obtained by
PmiR-296 (lane 2) was compensated by co-transfection with Amir-296 (lane 4).
8086 Nucleic Acids Research, 2011,Vol.39, No. 18(Figure 7E), indicating that miR-296 decreases p21
WAF1
mRNA level via interaction with the HU region in its
30UTR. Since this region also acts as a binding site
for Hu protein that regulates the stability of p21
WAF1,i t
is possible that miR-296 modulates the binding of the HU
proteins, resulting in an unstable p21
WAF1 mRNA.
hWNK4 (human with-no-lysine kinase-4, a member of
the serine-threonine protein kinase family associated
with hypertension) has also been shown to be down-
regulated by miR-296 at the post-transcriptional level in
Figure 6. miR-296 caused an increase in cell proliferation and cell viability. (A) Percent number of surviving U-2 OS and MCF 7 cells transfected
with either PmiR-296 or AmiR-296 or the two together. Bars represent standard deviation calculated from three independent experiments. (B)
Viability (MTT) assay of cells transfected with either PmiR-296 or AmiR-296. (C) PCNA staining of control and PmiR-296 treated cells. (D) Percent
increase in number of TIG-1 cells transfected with control or miR-296 expression vector.
Nucleic Acids Research, 2011,Vol.39, No. 18 8087a cell-speciﬁc pattern (63). Although we found that there is
40% homology between p21
WAF1-30UTR and hWNK4-
30UTR, the target sequence of miR-296 in the
hWNK4-30UTR (63) is different from the HU sequence
deﬁned in our study, suggesting that miR-296 may have
multiple target sequences. The molecular details of the
miR-296 binding to the HU region of p21
WAF1-30 UTR
and mechanism of p21
WAF1 suppression warrant further
studies.
We ﬁnally validated the effect of miR-296 on p21
WAF1
expression in a variety of cancer cell lines. The cells trans-
fected with miRNA expression plasmid were
examined for p21
WAF1 expression by immunostaining.
As shown in Figure 8A, miR-296 overexpressing
cells (green ﬂuorescence) showed decreased p21
WAF1
staining. Staining with the secondary antibody and an ir-
relevant control (actin) antibody were used as negative
controls. Similar results were obtained in four other
cell lines that showed either less or no p21
WAF1 staining
(red ﬂuorescence) in miR-296 transfected cells conﬁrming
that miR-296 downregulates p21
WAF1 (Figure 8B). We
also performed Q-PCR to determine the half-life of p21
mRNA in miR-296 transfected cells. As shown in
Figure 8C, p21 mRNA showed time-dependent decrease
during 48h post-transfection (about 70–80% decrease at
48h). Furthermore, as seen by immuno-cytostaining,
similar to the vector-driven expression of miR-296, syn-
thetic PmiR-296 caused decrease in p21
WAF1, whereas an
increase was observed in AmiR-296 transfected cells
(Figure 8D). The synthetic antagonist AmiR-296 was
designed to target miR-296 3p, suggesting that the latter
targets p21
WAF1.
Ampliﬁcation of the 20q13.32 genomic region has
been found in a wide variety of cancers (64–66).
miR-296 has been categorized as an Angio-miR, along
with miR-378 and miR-17-92 in the same gene cluster,
due to its contribution to tumor angiogenesis (67,68).
A study using co-culture of human U87 glioma and pri-
mary microvascular endothelial cells found that the
elongated endothelial cells showing tubule formation
and branching had upregulation of miR-296 (51). This
was conﬁrmed by culturing U87 glioma cells in angio-
genic cocktail-supplemented medium. Feed-forward regu-
lation was identiﬁed in which vascular endothelial
growth factor (VEGF) induced miR-296 expression and
that in turn targeted HGS, leading to increased levels of
VEGFR2 and PDGFRb proteins and an increase
response to VEGF. It was also induced by EGF and sug-
gested a complex growth factor crosstalk mechan-
ism leading to the development of angiogenesis. The
expression of miR-296 was found to be upregulated in
esophageal squamous cell cancer tissues and was asso-
ciated with high mortality among the patients.
Downregulation of miR-296 was shown to inhibit eso-
phageal cancer cell progression by regulation of multiple
signaling pathways including cyclin D1, p27,
P-glycoprotein, Bcl-2, MDR1 and Bax, and was
proposed as a potential target for intervention in this ma-
lignancy (69).
We have detected an upregulation of miR-296 in SV40
immortalized human cells, suggesting that it is an early
Figure 7. miR-296 strongly targets p21
WAF1 promoter. (A) Schematic
representation of luciferase reporter in which p53- 30UTR or p21
WAF1-
30UTR were linked to the 30-end of luciferase in a CMV
promoter-driven expression plasmid. (B) Luciferase activity of
Luc-p53-30UTR or Luc-p21
WAF1-30UTR constructs. A weak but signiﬁ-
cant decrease in luciferase linked to p53-30UTR was observed in
miR-296 transfected cells. miR-296 caused sharp decline in luciferase
expression from the Luc-p21
WAF1-30UTR construct. (C) Schematic rep-
resentation of luciferase reporter in which p21
WAF1-30UTR was serially
deleted to generate three constructs containing, HU binding site, CU
rich region1 and CU rich region 2. (D) Sequence of HU binding site,
CU rich region 1 and CU rich region 2. (E) Luciferase activity of the
Luc-p21
WAF1-30UTR construct and its deletion mutants containing HU
binding site, CU rich region 1 and CU rich region 2 showing that
downregulation of luciferase expression is caused by interaction of
miR-296 with the HU binding site.
8088 Nucleic Acids Research, 2011,Vol.39, No. 18event during cell transformation and carcinogenesis. We
have shown, for the ﬁrst time, that miR-296 is enriched in
many cancer cell lines and suppresses p53-p21
WAF1
pathway, an early event during immortalization of
human cells. We provide evidence that miR-296 targets
p21
WAF-1 by interacting with its 30 UTR. Since the
p53-p21
WAF1 pathway has several activities, including
control of cell cycle, apoptosis, control of centrosome du-
plication and genomic stability, that are lost in human
cancers, miR-296 may be a candidate therapeutic target
for cancer therapy.
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